🔗 Share this article

While America continues making historic adjustments to its immunization recommendations, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines throughout the pandemic and has focused upon possible deaths after COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Program

Public health authorities planned to reveal radical changes to the childhood vaccine schedule in December, aligning the US with the Danish national calendar, it is understood – a major change that would place the US out of step with a large portion of the international standard with little proof for improved outcomes. This reveal has been postponed until the next year.

In place of the director of the vaccine center, Dr. Høeg is scheduled to present at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to lead the center this calendar year.

Consolidating Power at the FDA

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it suggests a greater focus upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific childhood vaccine recommendations in the US to become more like Denmark's approach, a society with nationalized medicine and a population approximately the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Expertise

The appointee has no obvious experience in pharmaceutical research, regulation or leadership, which has been typical for previous directors of the biologics center. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a large organization. She has no expertise in drug approvals.”

Previous heads of the center would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, commented Janet Woodcock. “Objectively, she doesn’t have the sort of resume that former directors who headed CBER have had.”

The drug center has an vast workload at the agency, the former commissioner pointed out.

“Many people just focuses on the new drug program, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and more, and each of these must be looked after,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major management component to the job, which manages over 5,000 staff members. “It is a huge leadership role, if you perform it correctly,” the former official added.

Response and Contentious Initiatives

In response to concerns about Høeg’s credentials and whether this assignment indicates increased cooperation among agency officials on immunizations, a press secretary stated that the “questions stem from flawed assumptions”.

“Her resume is consistent with the responsibilities of her role,” the representative stated, pointing to the period Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's new expedited review system, a disputed expedited therapy clearance system that allegedly concerned her preceding directors. “How are these drugs being picked for this fast-track system? Who takes the calls?” Dr. Howard asked. “There is a lot of secrecy occurring at the FDA right now.”

In general, he remarked, “the agency appears to be shifting towards laxer regulations of most medications, with the exception of shots.”

Documented History on Vaccines

Regarding vaccines, Høeg has a more documented, if problematic, past, some experts have noted. She authored a research paper using unconfirmed volunteer-provided data to determine the frequency of heart inflammation following Covid vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “policy goals” for the new federal leadership featured altering rules for new vaccines and ending “unnecessary” vaccines, she remarked post-election on a online show. At the agency, Dr. Høeg has according to sources suggested barring adolescent males from obtaining Covid vaccines.

“She’s an thorough ideologue who commences with her beliefs and works backwards to accommodate the evidence in a highly deceptive, untruthful fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg joined other dissenters, {like|